ccr4 antagonist 2

CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.

C 021 dihydrochloride 是一种 CC 趋化因子受体 4 (CCR4) 拮抗剂，抑制人和小鼠的功能趋化性，IC50分别为 140 和 39 nM。C-021 (4-​Quinazolinamine, 2-​[1,​4'-​bipiperidin]​-​1'-​yl-​N-​cycloheptyl-​6,​7-​dimethoxy-) 可有效阻止人 CCL22 衍生的 [35S]GTPγS 与受体结合，IC50为 18 nM。

AZD-1678 is a potent CCR4 receptor antagonist.

GSK2239633 is a potent CC-chemokine receptor 4 antagonist with pIC50 of 7.9. The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.